These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 31412228)

  • 1. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
    Liu YQ; Li H; Liu JR; Lin YS
    Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
    [No Abstract]   [Full Text] [Related]  

  • 2. 30mCi radioactive iodine achieving comparative excellent response in intermediate/high-risk nonmetastatic papillary thyroid cancer: a propensity score matching study.
    Zhang Y; Wang C; Zhang X; Li H; Li X; Lin Y
    Endocrine; 2018 Dec; 62(3):655-662. PubMed ID: 30145748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIZE OF THE LARGEST METASTATIC FOCUS TO THE LYMPH NODE IS ASSOCIATED WITH INCOMPLETE RESPONSE OF PN1 PAPILLARY THYROID CARCINOMA.
    Deng Y; Zhu G; Ouyang W; Pan L; Feng H; Wu J; Chen P; Wang J; Xian J
    Endocr Pract; 2019 Sep; 25(9):887-898. PubMed ID: 31170371
    [No Abstract]   [Full Text] [Related]  

  • 4. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
    Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
    Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
    [No Abstract]   [Full Text] [Related]  

  • 5. Low activity versus high activity: noninferior response to radioiodine therapy in differentiated patients with extrathyroid extension.
    Wang C; Zhao T; Li H; Gao W; Lin Y
    Nucl Med Commun; 2017 May; 38(5):366-371. PubMed ID: 28362717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Curative Effect and Influencing Factors of N1 Stage Papillary Thyroid Micro-Carcinoma and Papillary Thyroid Non-Micro Carcinoma After Initial Radioactive Iodine Ablation Therapy.
    Yun C; Wu M; Xiao J; Liu Y; Zhang W; Cao J
    Cancer Manag Res; 2021; 13():1427-1434. PubMed ID: 33613032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.
    Zhao H; Gong Y
    Front Endocrinol (Lausanne); 2022; 13():960682. PubMed ID: 36034423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of response to Radioactive Iodine Therapy in Intermediate and high risk patients with papillary thyroid carcinoma.
    Keshavarzi A; Alaei-Shahmiri F; Fallahi B; Emami Z; Malek M; Khamseh ME
    BMC Endocr Disord; 2024 Jul; 24(1):112. PubMed ID: 39004697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer.
    Kim HK; Yoon JH; Cho JS; Kwon SY; Yoo SW; Kang HC
    Korean J Intern Med; 2020 Sep; 35(5):1164-1172. PubMed ID: 31352718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history, predictive factors of apparent disease (structural or biochemical) and spontaneous excellent response in patients with papillary thyroid carcinoma and indeterminate response to initial therapy with radioiodine.
    Rosario PW; Mourão GF
    Endocrine; 2022 Jun; 76(3):671-676. PubMed ID: 35347578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy.
    Jin M; Ahn J; Lee YM; Sung TY; Kim WG; Kim TY; Ryu JS; Kim WB; Shong YK; Jeon MJ
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):602-609. PubMed ID: 32981302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.
    Zhao T; Liang J; Guo Z; Li J; Lin Y
    Endocrine; 2016 Jul; 53(1):166-73. PubMed ID: 26782372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer.
    Lee CH; Jung JH; Son SH; Hong CM; Jeong JH; Jeong SY; Lee SW; Lee J; Ahn BC
    PLoS One; 2018; 13(8):e0202644. PubMed ID: 30118516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of factors influencing the clinical outcome after surgery and
    Li Y; Rao M; Zheng C; Huang J; Fang D; Xiong Y; Yuan G
    Front Endocrinol (Lausanne); 2022; 13():1015798. PubMed ID: 36313750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioactive iodine therapy strategies for distinct types of differentiated thyroid cancer: a propensity score-matched analysis.
    Guo H; Zhang N; Hu Y; Zhang F; Huang T; Shen N
    Front Endocrinol (Lausanne); 2023; 14():1158581. PubMed ID: 37664843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF
    Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
    Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioactive Iodine Therapy Decreases the Recurrence of Intermediate-Risk PTC With Low Thyroglobulin Levels.
    Tian T; Qi Z; Huang S; Wang H; Huang R
    J Clin Endocrinol Metab; 2023 Jul; 108(8):2033-2041. PubMed ID: 36715264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
    Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
    Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.